🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Robert J. Kreitman

National Cancer Institute

ORCID: 0000-0001-5141-1844
Immunology and MicrobiologyMedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 6%percentile
0.208Author DataRank

Indexed papers

3in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology
Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 3 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Top data-sharing exemplar

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Development of a distributed international patient data registry for hairy cell leukemia

Leukemia & lymphoma/Leukemia and lymphoma(2022)10.1080/10428194.2022.2109157
Top 65%
0.208DataRank
Top 65%3 citations

Mirela Anghelina, Jasmine Neal, James S. Blachly, Puneet Mathur, Omkar Lele +38 more

Papers

Driven by 21 papers — median percentile 35. Top paper: “Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study”.

Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study

Annals of Oncology(2022)10.1016/j.annonc.2021.12.014
N/A
7.1DataRank · unranked
352 citations

Robert J. Kreitman, Zev A. Wainberg, Y. Choi, Jan H.M. Schellens, Jean‐Charles Soria +9 more

Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial

Nature Medicine(2023)10.1038/s41591-023-02321-8
N/A
4.1DataRank · unranked
307 citations

Robert J. Kreitman, Zev A. Wainberg, Anas Gazzah, Ulrik Lassen, Alexander Stein +18 more

Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial

Journal of Hematology & Oncology(2021)10.1186/s13045-020-01004-y
N/A
1.9DataRank · unranked
86 citations

Robert J. Kreitman, Claire Dearden, Pier Luigi Zinzani, Julio Delgado, Tadeusz Robak +14 more

Dabrafenib plus trametinib in patients with relapsed/refractoryBRAFV600E mutation–positive hairy cell leukemia

Blood(2022)10.1182/blood.2021013658
N/A
1.1DataRank · unranked
42 citations

Philippe Moreau, Farhad Ravandi, Martin Hutchings, Anas Gazzah, Anne‐Sophie Michallet +12 more

Long term follow-up of a phase II study of cladribine with concurrent rituximab with hairy cell leukemia variant

Blood Advances(2021)10.1182/bloodadvances.2021005039
N/A
0.937DataRank · unranked
28 citations

Evgeny Arons, Maryalice Stetler‐Stevenson, Constance M. Yuan, Hao‐Wei Wang, Hong Zhou +13 more

Genetic regulation of OAS1 nonsense-mediated decay underlies association with COVID-19 hospitalization in patients of European and African ancestries

Nature Genetics(2022)10.1038/s41588-022-01113-z
N/A
0.742DataRank · unranked
140 citations

Megan L. Stanifer, Oscar Flórez-Vargas, Olusegun O. Onabajo, Brenen W. Papenberg, Muhammad Atif Zahoor +65 more

Hairy cell leukemia and COVID-19 adaptation of treatment guidelines

Leukemia(2021)10.1038/s41375-021-01257-7
N/A
0.578DataRank · unranked
46 citations

Leslie A. Andritsos, Versha Banerji, Jacqueline C. Barrientos, Seema A. Bhat, James S. Blachly +34 more

Consensus opinion from an international group of experts on measurable residual disease in hairy cell leukemia

Blood Cancer Journal(2022)10.1038/s41408-022-00760-z
N/A
0.477DataRank · unranked
23 citations

Robert J. Kreitman, Enrico Tiacci, Leslie A. Andritsos, Versha Banerji, Jacqueline C. Barrientos +40 more

In search of genetic factors predisposing to familial hairy cell leukemia (HCL): exome-sequencing of four multiplex HCL pedigrees

Leukemia(2020)10.1038/s41375-019-0702-7
N/A
0.464DataRank · unranked
7 citations

Anand Pathak, Samantha Jones, Ramita Dewan, Jessica Merberg, Sirisha Karra +17 more

Genetic regulation of OAS1 nonsense-mediated decay underlies association with risk of severe COVID-19

medRxiv(2021)10.1101/2021.07.09.21260221
N/A
0.396DataRank · unranked
13 citations

Megan L. Stanifer, Oscar Flórez-Vargas, Olusegun O. Onabajo, Muhammad Atif Zahoor, Brenen W. Papenberg +49 more

Expression of the muscle-associated gene MYF6 in hairy cell leukemia

PLoS ONE(2020)10.1371/journal.pone.0227586
N/A
0.330DataRank · unranked
8 citations

Hong Zhou, Mark Sokolsky, Daniel Gorelik, Katherine Potocka, Sarah Davies +13 more

Development of a distributed international patient data registry for hairy cell leukemia

Leukemia & lymphoma/Leukemia and lymphoma(2022)10.1080/10428194.2022.2109157
Top 65%
0.208DataRank
Top 65%3 citations

Mirela Anghelina, Jasmine Neal, James S. Blachly, Puneet Mathur, Omkar Lele +38 more

Series of Hairy Cell Leukemia Patients with Co-Existent Plasma Cell Disorders

Blood(2014)10.1182/blood.v124.21.5647.5647
N/A
0.165DataRank · unranked
2 citations

Sham Mailankody, Evgeny Arons, Raul C. Braylan, Mark Raffeld, Elizabeth Maestri +6 more

Complete Response in Hairy Cell Leukemia to Anti-CD22 CAR T-Cell Therapy

JCO Precision Oncology(2025)10.1200/po-25-00269
N/A
0.165DataRank · unranked
2 citations

Brett Schroeder, Evgeny Arons, Constance M. Yuan, Hao‐Wei Wang, Mark Raffeld +15 more

Phase 2 trial of rituximab with either pentostatin or bendamustine for multiply relapsed or refractory hairy cell leukemia

Blood(2025)10.1182/blood.2025031243
N/A
0.163DataRank · unranked
1 citations

Constance M. Yuan, Hao‐Wei Wang, Chirayu Mohindroo, Hong Zhou, Mark Raffeld +8 more

Phase 1 trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox combined with rituximab for relapsed/refractory hairy cell leukemia.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.7036
N/A
0DataRank · unranked
0 citations

Maryalice Stetler‐Stevenson, Constance M. Yuan, Hao‐Wei Wang, Hong Zhou, Mark Raffeld +10 more

Development of Recombinant Immunotoxins for Hairy Cell Leukemia

Biomolecules(2020)10.3390/biom10081140
N/A
0DataRank · unranked
26 citations

Ira Pastan, Robert J. Kreitman

Moxetumomab pasudotox as re-treatment for heavily-pretreated relapsed hairy cell leukemia

Leukemia & lymphoma/Leukemia and lymphoma(2021)10.1080/10428194.2021.1929959
N/A
0DataRank · unranked
13 citations

Steven Coutré, Hervé Ghesquières, Ira Pastan, Robert J. Kreitman, Ilana R. Yurkiewicz

Diagnosis and treatment of hairy cell leukemia as the COVID-19 pandemic continues

Blood Reviews(2021)10.1016/j.blre.2021.100888
N/A
0DataRank · unranked
11 citations

Evgeny Arons, Robert J. Kreitman

Concurrent chronic lymphocytic leukemia/small lymphocytic lymphoma and hairy cell leukemia: clinical, pathologic and molecular features

Leukemia & lymphoma/Leukemia and lymphoma(2020)10.1080/10428194.2020.1797007
N/A
0DataRank · unranked
11 citations

Ivo M.B. Francischetti, Hao‐Wei Wang, Inhye E. Ahn, Weixin Wang, Mark Raffeld +4 more

Characterization of B‐cell receptor clonality and immunoglobulin gene usage at multiple time points during active SARS‐CoV‐2 infection

Journal of Medical Virology(2023)10.1002/jmv.29179
N/A
0DataRank · unranked
0 citations

Kiersten Henry, Christopher Haas, M N Gould, Jack Tsintolas, Jack Mauter +5 more